Physician profile
Mark Very
NPI 1154369288
$3,521.62
in general payments reported to CMS, 2019-2025
23 companies · $923 in 2025
The $923 reported for 2025 was more than what 78% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $603 · 2020: $159 · 2021: $76.10 · 2022: $512 · 2023: $915 · 2024: $333 · 2025: $923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,138 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,137.70 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $968.43 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $535.77 | 2019-2025 | |
| Optinose US, INC. | $443.49 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $316.91 | 2019-2025 | Dupixent |
| Acclarent, INC | $311.69 | 2019-2023 | Trudi Nav Cable, Acclarent Aera, Acclarent Navwire |
| Intersect Ent, INC. | $207.20 | 2019 | |
| Inspire Medical Systems, INC. | $130.48 | 2023-2025 | Inspire |
| Kaleo, INC. | $98.13 | 2023-2024 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $72.70 | 2019-2024 | |
| Ars Pharmaceuticals Operations, INC. | $72.64 | 2025 | Neffy |
| Amgen INC. | $63.97 | 2025 | Tezspire |
| Aerin Medical INC. | $49.89 | 2025 | |
| Medtronic, INC. | $49.27 | 2023-2025 | Stealthstation S8 Platform, Propel |
| Medtronic USA, INC. | $36.04 | 2019 | |
| Eagle Pharmaceuticals, INC. | $25.84 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $25.43 | 2019 | |
| Paratek Pharmaceuticals, INC. | $22.48 | 2025 | Xhance |
| Smith+Nephew, INC. | $17.72 | 2021 | |
| Phathom Pharmaceuticals, INC. | $17.32 | 2024 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $17.08 | 2020 | |
| Tactile Systems Technology INC | $14.98 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.64 | 2019 | |
| Pfizer INC. | $11.52 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Very listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.